Genmab — Januar 2018
-
Men senere står der: ...high capacity for killing cancer cells expressing high or low levels of HER2 when administered as an antibody drug conjugate (ADC), no substantial agonistic effect on the proliferation of HER2-expressing cancer cells, and provide for effective ADCC-mediated killing of HER2-expressing cells, as well as any combination of the foregoing properties.
-
Is it pure coïncidence that this company (in Utrecht, just next to Genmab) announces first dosing of bispecific antibody targeting HER2 and HER3 receptors today?? Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=262078 -
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens https://clinicaltrials.gov/ct2/show/NCT03412565?term=daratumumab+OR+ofatumumab&lupd_s=01%2F25%2F2018&rank=4
-
Det går squ´meget godt nu
-
Som sagt før " Genmab er som en rutschebane i Fårup...det går SÅ hurtigt ned og OP
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind